June 1, 2024Journal of Clinical Oncology

Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response.

View Full Paper

Ask AI

Bookmark

Authors

YFYu FujiwaraTokyo Medical and Dental University SKShumei KatoUC San Diego Health System DNDaisuke NishizakiUC San Diego Health System

Discussion

Member takes

Implication

Randomized trial reveals that high CXCL13 expression predicts improved immune checkpoint inhibitor response in advanced cancer, highlighting the role of B cells in anti-tumor immunity.

Key Points

High cxcl13 transcriptome expression associates with favorable response to immune checkpoint inhibitors, defining responders with progression-free survival of six months or longer.
An odds ratio of 3.91 confirmed that elevated cxcl13 expression predicted therapy response, with the highest expression rates reaching 25% in head and neck tumors.
Transcriptome analysis of 34 B- and T-cell markers across 208 patients evaluated therapy outcomes, linking tumor microenvironment features to clinical responsiveness.
Highlights how cxcl13 recruits B cells to build tertiary lymphoid structures in the tumor microenvironment, indicating that B-cell pathways shape immunotherapy outcomes.

Cite This Study

Fujiwara et al. (2024) studied this question.

synapsesocial.com/papers/68e66eefb6db6435875f976b https://doi.org/10.1200/jco.2024.42.16_suppl.2626

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reveals that high CXCL13 expression predicts improved immune checkpoint inhibitor response in advanced cancer, highlighting the role of B cells in anti-tumor immunity.

Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response.

Discussion

Member takes

Implication

Key Points

Cite This Study

Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider